NEW YORK (GenomeWeb News) – Atossa Genetics said on Tuesday that it has submitted a premarket 510(k) notification with the US Food and Drug Administration for its ForeCYTE breast cancer test device.

The Seattle-based company voluntarily recalled the device in October after FDA voiced concerns about certain actions by Atossa, including the marketing of the device although FDA had not cleared or approved the ForeCYTE device for any indication.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.